Free Trial
→ ALERT: Drop these 5 stocks before the market opens tomorrow! (From Weiss Ratings) (Ad)tc pixel Free PKBO Stock Alerts

This company has been marked as potentially delisted and may not be actively trading.

Peak Bio (PKBO) Competitors

Peak Bio logo
Compare

PKBO vs. SNOA, ORGS, SXTC, SLXN, and CANF

Should you be buying Peak Bio stock or one of its competitors? The main competitors of Peak Bio include Sonoma Pharmaceuticals (SNOA), Orgenesis (ORGS), China SXT Pharmaceuticals (SXTC), Silexion Therapeutics (SLXN), and Can-Fite BioPharma (CANF). These companies are all part of the "pharmaceutical products" industry.

How does Peak Bio compare to Sonoma Pharmaceuticals?

Sonoma Pharmaceuticals (NASDAQ:SNOA) and Peak Bio (NASDAQ:PKBO) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their dividends, earnings, analyst recommendations, institutional ownership, risk, media sentiment, profitability and valuation.

In the previous week, Sonoma Pharmaceuticals' average media sentiment score of 0.00 equaled Peak Bio'saverage media sentiment score.

Company Overall Sentiment
Sonoma Pharmaceuticals Neutral
Peak Bio Neutral

2.0% of Sonoma Pharmaceuticals shares are owned by institutional investors. 24.6% of Sonoma Pharmaceuticals shares are owned by company insiders. Comparatively, 19.9% of Peak Bio shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Sonoma Pharmaceuticals
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Peak Bio
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

Peak Bio has a net margin of 0.00% compared to Sonoma Pharmaceuticals' net margin of -19.04%. Peak Bio's return on equity of 0.00% beat Sonoma Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Sonoma Pharmaceuticals-19.04% -42.56% -11.97%
Peak Bio N/A N/A -179.31%

Sonoma Pharmaceuticals has a beta of 1.28, meaning that its stock price is 28% more volatile than the S&P 500. Comparatively, Peak Bio has a beta of 1.75, meaning that its stock price is 75% more volatile than the S&P 500.

Sonoma Pharmaceuticals has higher revenue and earnings than Peak Bio. Sonoma Pharmaceuticals is trading at a lower price-to-earnings ratio than Peak Bio, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Sonoma Pharmaceuticals$14.29M0.15-$3.46M-$2.04N/A
Peak Bio$370K1.41-$12.83M-$0.16N/A

Summary

Sonoma Pharmaceuticals and Peak Bio tied by winning 6 of the 12 factors compared between the two stocks.

How does Peak Bio compare to Orgenesis?

Peak Bio (NASDAQ:PKBO) and Orgenesis (NASDAQ:ORGS) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their risk, valuation, dividends, analyst recommendations, profitability, media sentiment, institutional ownership and earnings.

In the previous week, Peak Bio's average media sentiment score of 0.00 equaled Orgenesis'average media sentiment score.

Company Overall Sentiment
Peak Bio Neutral
Orgenesis Neutral

Peak Bio has a beta of 1.75, meaning that its share price is 75% more volatile than the S&P 500. Comparatively, Orgenesis has a beta of 3.07, meaning that its share price is 207% more volatile than the S&P 500.

22.6% of Orgenesis shares are held by institutional investors. 19.9% of Peak Bio shares are held by insiders. Comparatively, 5.7% of Orgenesis shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Peak Bio has higher earnings, but lower revenue than Orgenesis. Peak Bio is trading at a lower price-to-earnings ratio than Orgenesis, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Peak Bio$370K1.41-$12.83M-$0.16N/A
Orgenesis$662K4.65-$55.36M-$11.51N/A

Peak Bio has a net margin of 0.00% compared to Orgenesis' net margin of -3,827.81%.

Company Net Margins Return on Equity Return on Assets
Peak BioN/A N/A -179.31%
Orgenesis -3,827.81%N/A -130.18%

Summary

Orgenesis beats Peak Bio on 6 of the 10 factors compared between the two stocks.

How does Peak Bio compare to China SXT Pharmaceuticals?

China SXT Pharmaceuticals (NASDAQ:SXTC) and Peak Bio (NASDAQ:PKBO) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their media sentiment, earnings, profitability, risk, analyst recommendations, valuation, institutional ownership and dividends.

5.0% of China SXT Pharmaceuticals shares are held by institutional investors. 4.0% of China SXT Pharmaceuticals shares are held by company insiders. Comparatively, 19.9% of Peak Bio shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Company Net Margins Return on Equity Return on Assets
China SXT PharmaceuticalsN/A N/A N/A
Peak Bio N/A N/A -179.31%

China SXT Pharmaceuticals has higher revenue and earnings than Peak Bio.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
China SXT Pharmaceuticals$1.74M0.99-$3.30MN/AN/A
Peak Bio$370K1.41-$12.83M-$0.16N/A

China SXT Pharmaceuticals has a beta of 1.96, indicating that its stock price is 96% more volatile than the S&P 500. Comparatively, Peak Bio has a beta of 1.75, indicating that its stock price is 75% more volatile than the S&P 500.

In the previous week, China SXT Pharmaceuticals' average media sentiment score of 0.00 equaled Peak Bio'saverage media sentiment score.

Company Overall Sentiment
China SXT Pharmaceuticals Neutral
Peak Bio Neutral

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
China SXT Pharmaceuticals
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Peak Bio
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

Summary

China SXT Pharmaceuticals beats Peak Bio on 6 of the 8 factors compared between the two stocks.

How does Peak Bio compare to Silexion Therapeutics?

Peak Bio (NASDAQ:PKBO) and Silexion Therapeutics (NASDAQ:SLXN) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their earnings, profitability, risk, valuation, media sentiment, analyst recommendations, institutional ownership and dividends.

In the previous week, Silexion Therapeutics had 1 more articles in the media than Peak Bio. MarketBeat recorded 1 mentions for Silexion Therapeutics and 0 mentions for Peak Bio. Silexion Therapeutics' average media sentiment score of 0.84 beat Peak Bio's score of 0.00 indicating that Silexion Therapeutics is being referred to more favorably in the news media.

Company Overall Sentiment
Peak Bio Neutral
Silexion Therapeutics Positive

11.0% of Silexion Therapeutics shares are owned by institutional investors. 19.9% of Peak Bio shares are owned by insiders. Comparatively, 5.0% of Silexion Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Silexion Therapeutics has lower revenue, but higher earnings than Peak Bio. Peak Bio is trading at a lower price-to-earnings ratio than Silexion Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Peak Bio$370K1.41-$12.83M-$0.16N/A
Silexion TherapeuticsN/AN/A-$11.91M-$11.10N/A

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Peak Bio
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
Silexion Therapeutics
1 Sell rating(s)
1 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00

Peak Bio has a beta of 1.75, meaning that its share price is 75% more volatile than the S&P 500. Comparatively, Silexion Therapeutics has a beta of -0.29, meaning that its share price is 129% less volatile than the S&P 500.

Peak Bio's return on equity of 0.00% beat Silexion Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Peak BioN/A N/A -179.31%
Silexion Therapeutics N/A -387.82%-144.68%

Summary

Silexion Therapeutics beats Peak Bio on 8 of the 13 factors compared between the two stocks.

How does Peak Bio compare to Can-Fite BioPharma?

Peak Bio (NASDAQ:PKBO) and Can-Fite BioPharma (NYSE:CANF) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, media sentiment, profitability, risk, earnings, analyst recommendations, dividends and valuation.

In the previous week, Can-Fite BioPharma had 2 more articles in the media than Peak Bio. MarketBeat recorded 2 mentions for Can-Fite BioPharma and 0 mentions for Peak Bio. Can-Fite BioPharma's average media sentiment score of 0.34 beat Peak Bio's score of 0.00 indicating that Can-Fite BioPharma is being referred to more favorably in the news media.

Company Overall Sentiment
Peak Bio Neutral
Can-Fite BioPharma Neutral

21.0% of Can-Fite BioPharma shares are owned by institutional investors. 19.9% of Peak Bio shares are owned by company insiders. Comparatively, 0.8% of Can-Fite BioPharma shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Company Net Margins Return on Equity Return on Assets
Peak BioN/A N/A -179.31%
Can-Fite BioPharma N/A N/A N/A

Can-Fite BioPharma has a consensus target price of $65.00, indicating a potential upside of 1,757.14%. Given Can-Fite BioPharma's stronger consensus rating and higher probable upside, analysts clearly believe Can-Fite BioPharma is more favorable than Peak Bio.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Peak Bio
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
Can-Fite BioPharma
0 Sell rating(s)
2 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.33

Peak Bio has a beta of 1.75, meaning that its stock price is 75% more volatile than the S&P 500. Comparatively, Can-Fite BioPharma has a beta of 1.09, meaning that its stock price is 9% more volatile than the S&P 500.

Can-Fite BioPharma has higher revenue and earnings than Peak Bio. Peak Bio is trading at a lower price-to-earnings ratio than Can-Fite BioPharma, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Peak Bio$370K1.41-$12.83M-$0.16N/A
Can-Fite BioPharma$405K5.66-$7.63M-$35.80N/A

Summary

Can-Fite BioPharma beats Peak Bio on 10 of the 14 factors compared between the two stocks.

Get Peak Bio News Delivered to You Automatically

Sign up to receive the latest news and ratings for PKBO and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PKBO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

PKBO vs. The Competition

Export
MetricPeak BioBiological Products IndustryMedical SectorNASDAQ Exchange
Market Cap$520K$329.01M$6.25B$11.77B
Dividend YieldN/AN/A2.74%5.26%
P/E Ratio-0.14N/A29.2527.07
Price / Sales1.41189.48504.6873.47
Price / CashN/A22.4443.3053.90
Price / Book-0.034.739.676.69
Net Income-$12.83M-$132.96M$3.55B$332.64M

Peak Bio Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
PKBO
Peak Bio
N/A$0.02
flat		N/AN/A$520K$370KN/A3
SNOA
Sonoma Pharmaceuticals
0.7052 of 5 stars		$1.20
+9.1%		N/AN/A$2.08M$14.29MN/A180
ORGS
Orgenesis
N/A$0.40
flat		N/AN/A$2.07M$662KN/A150
SXTC
China SXT Pharmaceuticals
0.6099 of 5 stars		$2.07
+0.5%		N/AN/A$1.99M$1.74MN/A90
SLXN
Silexion Therapeutics
1.1701 of 5 stars		$0.60
-2.3%		N/AN/A$1.99MN/AN/AN/A

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:PKBO) was last updated on 5/5/2026 by MarketBeat.com Staff.
From Our Partners
SpaceX eyes a 1.75 trillion valuation - here's what to know
Elon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...
Brownstone Research | Sponsoredtc pixel
Iran's New Leader Just Said Something That Should Terrify Every American
Iran's Supreme Leader has declared the Strait of Hormuz closed as leverage against the U.S. - and with 40% of ...
American Alternative | Sponsoredtc pixel
Your book attached
Your Download Link (Expiring) If you still haven't downloaded the free Simple Options Trading For Beginners...
Profits Run | Sponsoredtc pixel
My feud with Zohran Mamdani
Emmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...
Stansberry Research | Sponsoredtc pixel
Sell 99% of Your Stocks, Do THIS Instead…
Millionaire Trader Exposes: "The Single Stock Income Plan" With over 6,000 stocks on the market to choose ...
The Oxford Club | Sponsoredtc pixel
Trade this between 9:30 and 10:45 am EST
The first 75 minutes of the trading day may be the most overlooked window for consistent opportunities.If you ...
Base Camp Trading | Sponsoredtc pixel
Iran War Shock: What I Was Told In That Private Meeting
You’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...
Banyan Hill Publishing | Sponsoredtc pixel
Elon Unveils AI Passive Income Stream for Millions of Americans
During Tesla's last earnings call, Elon Musk outlined a new AI-driven approach he says could generate $30,000-...
InvestorPlace | Sponsoredtc pixel